The purpose of this study is to examine the use of a new investigational medication for the
treatment of moderate plaque-type psoriasis. The study medication is rimegepant, an orally
administered small molecule competitive inhibitor of the calcitonin gene-related peptide
(CGRP) receptor. This medication, rimegepant, has been approved by the FDA under the trade
name Nurtec for the treatment of acute migraine. However, rimegepant has not been studied in
the treatment of moderate plaque-type psoriasis and is investigational for this indication.